Price target
69.500.00 0.00%
The 4 analysts offering 1 year price forecasts for PK5 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 5 analysts giving stock ratings to PK5 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
PK5 EPS for the last quarter is −1.71 CHF despite the estimation of −2.01 CHF. In the next quarter EPS is expected to reach 0.94 CHF. Track more of BASILEA PHARMACEU financials and stay on top of what is up with the company.
In the next quarter BASILEA PHARMACEU revenue is expected to reach 86.00 M CHF. Check out BASILEA PHARMACEU revenue and earnings and make informed decisions.
According to analysts, PK5 price target is 69.50 CHF with a max estimate of 94.00 CHF and a min estimate of 52.00 CHF. Check if this forecast comes true in a year, meanwhile watch BASILEA PHARMACEU stock price chart and keep track of the current situation with PK5 news and stock market news.
We've gathered opinions of 5 analysts rating PK5 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.